• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Solution Center
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Solution Center
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Pharma Supply Chains: From Fragile to Agile

    Advanced Manufacturing and a Roadmap to the Facility of the Future

    Solving Pharma’s Underlying Rebate Leakage Problem

    Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges

    Revolutionizing Pharma’s Supply Chain
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Univercells Expands into the U.S. With New Offices in Andover, MA

    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment

    Ionis, Roche Partner on RNA-targeted Programs for AD and HD

    Sanner Group Opens Second Manufacturing Facility in China

    Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Univercells Expands into the U.S. With New Offices in Andover, MA

    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment

    Sanner Group Opens Second Manufacturing Facility in China

    Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems

    "3 Key Trends" with Srinivasan Shanmugam
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Pharmaceutical Continuous Manufacturing: USP Technical Guide

    Mikart Expands Production and Packaging Capabilities

    Flavor Masking for Rx and OTC Drugs

    Prefilled Syringe Production: Filling a Need with Modern Equipment

    Making the Complex, Simple: A Roadmap for Your OSD Journey
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment

    Ionis, Roche Partner on RNA-targeted Programs for AD and HD

    Modern Partnerships with CROs

    Merck KGaA, Quris-AI Expand Collaboration

    BioCity, AstraZeneca Partner on Treatment of Advanced HCC
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges

    Rentschler Biopharma’s ATMP UK Facility Receives MHRA Approval

    Aurisco's Manufacturing Site in China Clears FDA Inspection

    LighthouseAI Secures $2.25M Investment to Grow Supply Chain Products

    Valisure, DoD Conduct Pharmaceutical Quality Risk Assessment Study
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    AMERIPHARMA

    Quotient Sciences

    CMC Pharmaceuticals

    Bachem

    Lannett CDMO
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    AMERIPHARMA

    Quotient Sciences

    CMC Pharmaceuticals

    Bachem

    Lannett CDMO
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Top Companies Report

    04 AstraZeneca

    ...

    07.16.08

    #4 AstraZeneca



    15 Stanhope Gate, London W1K 1LN, UK
    Tel: (44) 00 7304 5000 Fax: (44) 020 7304 5151
    www.astrazeneca.com



    Headcount 67,000  
    Year Established 1999  
    Pharma Revenues* $28,713 +12%
    Total Revenues* $29,559 +12%
    Net Income $7,983 -7%
    R&D Budget $5,162 +32%

    * Revenues include seven months of MedImmune results

     

     

    Top Selling Drugs
    Drug Indication Sales (+/-%)
    Nexium peptic ulcer, acid reflux $5,216 +1%
    Seroquel antipsychotic $4,027 +18%
    Crestor cholesterol $2,796 +38%
    Arimidex oncology $1,730 +15%
    Symbicort asthma $1,575 +33%
    Pulmicort asthma $1,454 +13%
    Seloken/Toprol hypertension $1,438 -20%
    Casodex prostate cancer $1,335 +11%
    Atacand hypertension $1,287 +16%
    Losec/Prilosec peptic ulcer, acid reflux $1,143 -17%
    Zoladex oncology $1,104 +10%
    Merrem anti-infection $773 +28%

    Account for 83% of total pharma sales, down from 84% in 2006.

     

    PROFILE



    AstraZeneca has been haunted by recent failures, as several late-stage crashes and commercial mishaps have left it vulnerable. Are things turning around? In the last three months, AZ has negotiated its way out of generic exposure for its top seller (Nexium) and won a court battle extending the patent protection for its #2 seller. Those products added up to more than $9.0 billion in 2007 revenues, so their loss would have spelled doom for the company before its 10th anniversary.

    Speaking of anniversaries, June 2008 marked one year since AZ closed on its $15.5 billion acquisition of MedImmune. As I pointed out in GSK’s profile, major pharma companies like to talk about how they’re going to incorporate the entrepreneurialism and flexibility of biopharmas into their existing companies. AZ has been a bit more honest about employing MedImmune for its infrastructure and experience in developing biologics, rather than paying lip service to how they’ll incorporate some sort of freewheeling maverick biotech spirit into a 67,000-employee company.
    The Lowe Down: AZ

    AstraZeneca’s been cutting back its research this year – but then, you could substitute a lot of other company names and that statement would fit just fine. The research organization seems to be unafraid to try new things, if all those fragment-based drug design papers they’re publishing are any measure. That may be a hopeful sign, because new things definitely seem to be needed around the industry. (Of course, the literature being what it is, those papers might only mean that they weren’t afraid to try new things four years ago).

    They’ll be needing some new stuff soon. The Vytorin mess over at Schering-Plough has helped out AZ’s statin sales, but you can’t just live on other people’s problems. The Nexium franchise is on the downward side of its life, and there aren’t as many things to replace it as there looked to be a few years ago. The company seems to be doing the right things: here’s hoping that that’s enough.

    -Derek Lowe

    The acquisition had the immediate effect of bumping AZ’s clinical projects (NMEs and line extensions) from 71 to 95, and doubled the number of projects in Phase III to 10. In February 2008, the company filed a BLA for Numax, a next-generation version of Synagis, a treatment for respiratory syncytial virus (RSV), so the purchase has generated some value.

    Still, to my eye, there are moments when MedImmune looks like AZ’s accidental poison pill, keeping unwanted suitors at bay. I’m sure that wasn’t the key driver in acquiring MedImmune; I still take AZ management at face value when they said that MedImmune was intended to deliver a fully-formed biopharma infrastructure, capable of “accelerat[ing] delivery of its biologics strategy while lowering its execution risk,” to quote AZ chief executive officer David Brennan.

    That said, I can see how paying off that $15.5 billion bill, on top of the standard problems involved with integrating a major pharma, would make takeover players back off. Especially now that the two top figures at MedImmune have moved on to greener pastures.

    Less than two weeks after the acquisition’s anniversary, MedImmune chief executive David Mott and R&D head James Young, Ph.D. chose to leave AZ. The Wall Street Journal’s Health Blog noted that Mr. Mott — who’s sticking around through July — and Dr. Young signed retention term sheets to stay with the company for one year after the merger.

    Mr. Mott received a payment of around $145 million from AZ’s buyout, which must have made it awfully difficult to make it through the workday. I’d have set up my computer with a countdown clock to notch off the seconds until the one-year term expired, at which point I would run home and dive into a swimming pool filled with cash, but that’s just me.

    Not Dead Yet



    I don’t mean to imply that it’s all doom and gloom at AZ. The company’s LDL drug, Crestor, gained almost $800 million in sales in 2007; FDA approval of asthma treatment Symbicort helped that drug reach $1.5 billion in 2007 sales, and Seroquel is picking up new indications as it moves up to become AZ’s top seller.
    The Name’s Al. Albireo.

    Another interesting aspect of AZ’s restructuring efforts is its interest in licensing out development programs. Just last year, AZ put forth a huge investment to in-license Bristol-Myers Squibb’s saxagliptin, which has a chance of being the third DPP-4 inhibitor to reach the U.S. diabetes market. A year later, AZ spun off some of its GI research to a new firm called Albireo. The company is funded by several growth capital firms (AZ still has a “significant minority interest” in it) and covers one clinical and several preclinical programs for GI disorders. The new company is located in AZ’s old digs in Gothenburg, Sweden. Where it discovered Nexium.

    Crestor “only” increased 16% in 1Q08, but the company noted that it was the only branded statin to gain market share during that period. It’ll likely perform even better in 2Q08, given the fallout from the Vytorin mess (see Merck and Schering-Plough’s profiles for more on that). In November 2007, Crestor was approved by the FDA to treat atherosclerosis, and AZ recently began a trial to test Crestor against Lipitor in that indication.

    In addition to that NuMax filing, AZ has two other NDA filings planned: Onglyza (saxagliptin), the diabetes drug it in-licensed from Bristol-Myers Squibb last year, and Zactima, a cancer treatment that received fast-track status from the FDA in 2006 for thyroid cancer.

    In-or-Outsourcing?



    For our readership, the most interesting event involving AstraZeneca last year was its on-again, off-again statements about its plans to outsource almost all of its manufacturing within the decade.

    The kerfluffe began in September 2007. In a London Times article by Robin Pagnamenta, AZ’s executive vice president of operations, David Smith, commented, “Manufacturing for AstraZeneca is not a core activity . . . AstraZeneca is about innovation and brand-building . . . There are lots of people and organisations that can manufacture better than we can.”

    He added that the company’s priority was to outsource all API manufacturing, preferably to the far east, and eventually move drug manufacturing out of house, too. He remarked, “We would own the IP, the research, branding and the quality and safety issues . . . but [everything else] would be outsourced. The idea is to take out as many stages as you can.” Mr. Smith’s comments were almost immediately denied by AZ, which presented his remarks as hypotheticals.

    When our online editor Joanna Cosgrove asked AZ to clarify things, Joan E. Pitt, AZ’s director of communications, global operations, commented, “We currently outsource API production in Europe and India, and are currently looking at outsourcing intermediates from China. And, under the strategy we will continue to look at opportunities in both Europe and Asia.”

    A few months later, however, AZ performed another about face. In AZ’s “authorized generic” agreement with Ranbaxy over Nexium, the two companies made an interesting side agreement. In addition to authorizing Ranbaxy to make a generic of the drug in 2014, with its 180-day exclusivity, AZ will also allow Ranbaxy to manufacture the API for Nexium in 2009 and formulate some of the U.S. supply of it around May 2010.

    In a conference call about the Ranbaxy deal, Mr. Brennan said, “This move is absolutely consistent with our supply chain strategy . . . We have been looking to outsource our manufacturing where we can . . . we have long-term plans to exit all API production over the next five to 10 years.”

    Ms. Cosgrove called Ms. Pitt again, and she responded, “We have now stated our intent to outsource API manufacture over the next five to ten years . . . Please note this is only API manufacture [for Nexium] and not all manufacture. As noted . . . the full outsource of supply and manufacturing activities is not part of the AZ strategy.”

    I’ll be interested to see if the agreement holds up, since there are several generic companies still suing to get the Nexium patents overturned. If it does, this may shed some light on how AZ plans to tackle the outsourcing of its mature products.

    I’d love to see a major pharma company blow up the existing infrastructure and radically rethink its very nature. I just don’t get how they plan to source their new compounds (and, yes, I’m assuming they will have new compounds).

    Previous Profile: Sanofi-Aventis // Next Profile: Merck


    Top 20 Pharma Report homepage

    Related Searches
    • api manufacturing
    • Manufacturing
    • Development
    • pharma companies
    Suggested For You
    NuvOx Completes Construction of Expanded Manufacturing Facility NuvOx Completes Construction of Expanded Manufacturing Facility
    January 2021: Auction of BioPharma Lab Equipment From Icagen January 2021: Auction of BioPharma Lab Equipment From Icagen
    Mogene Mogene
    Frontida BioPharm Launches Expansion Efforts Frontida BioPharm Launches Expansion Efforts
    Recro Gainesville Expands Mfg. Capabilities Recro Gainesville Expands Mfg. Capabilities
    Diverse Products And Technologies Delivered Diverse Products And Technologies Delivered
    PPD Expands Vaccine Development Lab PPD Expands Vaccine Development Lab
    UPM Celebrates 100-Years of Mfg. at Tennessee Site UPM Celebrates 100-Years of Mfg. at Tennessee Site
    Sanofi, MedImmune in RSV Alliance Sanofi, MedImmune in RSV Alliance
    Allergan, AstraZeneca Enter Licensing Agreement Allergan, AstraZeneca Enter Licensing Agreement
    Unilife Unveils New Leadership Team Unilife Unveils New Leadership Team
    9 AstraZeneca 9 AstraZeneca
    Novavax Names Biostatistics VP Novavax Names Biostatistics VP
    06 AstraZeneca, plc 06 AstraZeneca, plc
    Who Executes The Executives? Who Executes The Executives?

    Related Breaking News

    • Bio News | Breaking News | Facilities | Industry News
      NuvOx Completes Construction of Expanded Manufacturing Facility

      NuvOx Completes Construction of Expanded Manufacturing Facility

      Will manufacture its lead product, NanO2, for clinical trials and commercial supply after FDA approval.
      Tim Wright, Editor, Contract Pharma 05.03.21

    • January 2021: Auction of BioPharma Lab Equipment From Icagen

      ...

    • Mogene

      ...
      Craig Morley, CEO 11.17.20


    • Breaking News | Facilities | Industry News | Inspections
      Frontida BioPharm Launches Expansion Efforts

      Frontida BioPharm Launches Expansion Efforts

      Comes on heels of receiving FDA clearance
      05.26.17

    • Breaking News | Facilities | Industry News | Solid Dosage/Creams/Ointments | Solid Dosage/Semi-solids
      Recro Gainesville Expands Mfg. Capabilities

      Recro Gainesville Expands Mfg. Capabilities

      Installs new tableting equipment and grows development team
      05.24.17

    Loading, Please Wait..
    Breaking News
    • Univercells Expands into the U.S. With New Offices in Andover, MA
    • Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment
    • Ionis, Roche Partner on RNA-targeted Programs for AD and HD
    • Sanner Group Opens Second Manufacturing Facility in China
    • Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems
    View Breaking News >
    CURRENT ISSUE

    September 2023

    • Pharma Supply Chains: From Fragile to Agile
    • Overcoming Stressors in Knowledge Transfer
    • Innovations in Pharma Packaging
    • HPAPI Manufacturing Trends
    • Sustainable Packaging in Pharma: No Longer a Pipe Dream
    • Revolutionizing Pharma’s Supply Chain
    • Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges
    • Solving Pharma’s Underlying Rebate Leakage Problem
    • Advanced Manufacturing and a Roadmap to the Facility of the Future
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    D2C Supplement Brand Launches Blood Sugar Support Supplement, Gluco-Control
    Natrol Launches First Non-Melatonin Sleep Supplement
    Metagenics Releases Consumer Survey on Menopausal Support Supplement
    Coatings World

    Latest Breaking News From Coatings World

    Coating Additives Market Worth $10.5B by 2028: MarketsandMarkets
    California Sports Surfaces Celebrates 70 Years
    ROSS Offers Cost-Effective, Expertly Reconditioned Equipment
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    MPO's Most-Read Stories This Week—Sept. 30
    Dentsply Sirona Names Former NuVasive CEO Lucier as Chairman
    SeaStar Medical Gets Breakthrough Nod for Selective Cytopheretic Device
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Univercells Expands into the U.S. With New Offices in Andover, MA
    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment
    Ionis, Roche Partner on RNA-targeted Programs for AD and HD
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    MAV Beauty Recruits Former Elizabeth Arden CEO Scott Beattie
    YSL Beauty Taps Finn Wolfhard, Lil Yachty & More for Fragrance Campaign
    74% of Makeup Users Open to Affordable ‘Dupes,’ Mintel Says
    Happi

    Latest Breaking News From Happi

    Is Dr. Barbara Sturm Skincare Considering a Sale?
    YSL Beauty Welcomes Five Foremost Artists to Represent New Fragrance
    Christian Siriano Appointed Olay’s First Chief Drop Officer
    Ink World

    Latest Breaking News From Ink World

    MicroDynamics, All Printing Resources Partner to Represent Veritas
    Weekly Recap: Wikoff Color, BASF, Latin America Top This Week’s Stories
    Siegwerk’s Climate Targets Validated by SBTi
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    SABIC and partners launch bio-based IML solution for food packaging
    tesa completes expansion of Michigan manufacturing facility
    Comexi and Asahi to host 'Effortless Platemaking' event
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Greentech Introduces Air Filter with Advanced Odor Elimination
    Ontex Divests Pakistan Operations to ASAIA Holding
    Goodnites Bedwetting Underwear Recognized by Good Housekeeping
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    ODT's Most-Read Stories This Week—Sept. 30
    Lazurite Adds Benchmark Medical as a Distributor for its ArthroFree Wireless Camera System
    ChitogenX Granted New U.S., Canadian ORTHO-R Patent
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Weekly Recap: Mergers and Acquisitions, First Solar Top This Week’s Stories
    Jabil Posts Fourth Quarter, Fiscal Year 2023 Results
    Ink-Borne ‘Chiplets’ Could Lead to Printable Displays, Electronics and More

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login